Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta‐analysis. Issue 12 (26th October 2022)

• Record Type: Journal Article
• Authors: He, Zhu‐Han; Qiu, Shuo‐Cheng; Huang, Zhi‐Wei; Zhang, Guo‐Qiang; An, Qing‐Qing; Qu, Feng; Wang, Na
• Is Part Of: Dermatologic therapy. Volume 35:Issue 12(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-10-26
• Subjects: chronic induced urticaria -- chronic spontaneous urticaria -- meta‐analysis -- omalizumab -- systematic review; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15928
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: This meta‐analysis aimed to assess the efficacy of omalizumab in the treatment of refractory‐to‐antihistamines chronic induced urticaria (CIndU) in comparison with that of refractory‐to‐antihistamines chronic spontaneous urticaria (CSU). We retrieved interventional studies and observational studies on omalizumab efficacy to CIndU patients and efficacy comparison between CSU and CIndU both refractory to H1‐antihistamines in electronic databases (accessed till May 2022). The odd ratio (OR) and 95% confidence interval (CI) was calculated with a random‐effect model in this meta‐analysis. The majority of patients with different CIndU subtypes gained complete or partial response and good safety after omalizumab treatment. A total of five studies with 355 CSU patients and 103 CIndU patients were included for the meta‐analysis. There was no significant difference in the efficacy of omalizumab in the treatment of CSU and CIndU (OR ‐0.83, 95% CI [0.84, 2.21], P > 0.05). Based on the validity of omalizumab in the treatment of various CIndU subtypes and non‐differential efficacy between CSU and CIndU, it is reasonable to list omalizumab as a third‐line treatment of refractory CIndU.